PD-1 and PD-1 ligands: from discovery to clinical application.
about
Increasing disparities between resource inputs and outcomes, as measured by certain health deliverables, in biomedical researchThe PD-1 pathway in tolerance and autoimmunityPD-L1 expression in human cancers and its association with clinical outcomesMelanoma immunotherapy dominates the fieldA Mini-Review for Cancer Immunotherapy: Molecular Understanding of PD-1/PD-L1 Pathway & Translational Blockade of Immune CheckpointsNon-small cell lung cancer: current treatment and future advancesImmune checkpoint blockade therapy for bladder cancer treatmentProgrammed Cell Death-1 Polymorphisms Decrease the Cancer Risk: A Meta-Analysis Involving Twelve Case-Control StudiesMedical treatment for gastro-entero-pancreatic neuroendocrine tumoursPD-1/PD-L1 blockade in cancer treatment: perspectives and issuesPredictive factors of activity of anti-programmed death-1/programmed death ligand-1 drugs: immunohistochemistry analysisOncolytic Adenovirus: Strategies and Insights for Vector Design and Immuno-Oncolytic ApplicationsExploiting the Immunomodulatory Properties of Chemotherapeutic Drugs to Improve the Success of Cancer ImmunotherapyThe anticancer immune response of anti-PD-1/PD-L1 and the genetic determinants of response to anti-PD-1/PD-L1 antibodies in cancer patientsNivolumab in the treatment of malignant melanoma: review of the literatureOptimal management of metastatic melanoma: current strategies and future directionsUpdate on the challenges and recent advances in cancer immunotherapyThe PD-1/PD-L1 complex resembles the antigen-binding Fv domains of antibodies and T cell receptorsCrystal structure of the complex between programmed death-1 (PD-1) and its ligand PD-L2PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis.Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in MelanomaThe blockade of immune checkpoints in cancer immunotherapySafety and Activity of Anti–PD-L1 Antibody in Patients with Advanced CancerCombination Approaches with Immune-Checkpoint Blockade in Cancer TherapyAnti-programmed cell death protein-1/ligand-1 therapy in different cancersThe role of the PD-1 pathway in autoimmunity and peripheral tolerancePD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumorsPD-L1, PD-L2 and PD-1 expression in metastatic melanoma: Correlation with tumor-infiltrating immune cells and clinical outcome.Autocrine adenosine signaling promotes regulatory T cell-mediated renal protection.Lipidoid Nanoparticles Containing PD-L1 siRNA Delivered In Vivo Enter Kupffer Cells and Enhance NK and CD8(+) T Cell-mediated Hepatic Antiviral Immunity.Chronically inflamed livers up-regulate expression of inhibitory B7 family members.PD-1/PD-L blockade prevents anergy induction and enhances the anti-tumor activities of glycolipid-activated invariant NKT cellsPD-1 regulates neural damage in oligodendroglia-induced inflammation.Regulatory T cells and human myeloid dendritic cells promote tolerance via programmed death ligand-1.PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation.Prognostic role of programmed-death ligand 1 (PD-L1) expressing tumor infiltrating lymphocytes in testicular germ cell tumors.Anti-PD-1 antibody significantly increases therapeutic efficacy of Listeria monocytogenes (Lm)-LLO immunotherapy.Programmed cell death-1 is expressed in large retinal ganglion cells and is upregulated after optic nerve crush.Vitamin D increases programmed death receptor-1 expression in Crohn's disease.Inflammatory cytokines compromise programmed cell death-1 (PD-1)-mediated T cell suppression in inflammatory arthritis through up-regulation of soluble PD-1.
P2860
Q24289253-FFA72FD1-7975-4387-BF0F-7CEE912ABD28Q24633549-3A0DDE6D-AD7B-49ED-9AC5-FAD3CA8783E8Q26738361-3B29A69E-6BD4-4F07-9C12-2F32302F4EC9Q26738671-E16FFDEA-8F91-455A-B3D8-17D8436D87CCQ26738729-9B6A92D1-F674-4E66-8F19-414E205B1CCBQ26740333-E5E82CC4-7DE6-4E7C-B8E0-8A4C58992867Q26744139-B448AEDA-6C9C-498C-8131-4E8F51A55A33Q26749244-47C40835-2F84-4BA7-91C9-14A613F5C4E5Q26751659-DB5321D8-88EC-4EF8-8DBB-DE864C5CF072Q26768641-D58A0161-747F-423E-B237-CF9386D6AFFCQ26769728-6A6AEAD2-36DA-46F1-8F13-AAB6F9A85DD1Q26776553-4363376B-D75B-4376-9509-2C3F76AE6495Q26779184-0E4C6095-1F55-4A56-8F9E-E4163916C153Q26797478-3325A8A4-612F-4A32-A209-97BCECA25EC2Q26798330-58626293-501E-4DD3-9EB8-4489EF65EC63Q26997338-657AE202-4B1D-4F47-9C66-7D102263942BQ27014693-4F518A82-0A8E-4214-89A4-51FCD9DA54D6Q27649885-124FE84F-E200-4FB5-996E-7A1B7E4ED1A1Q27651269-9F32A590-BEA6-485D-A03D-4B5518681A4CQ27853353-07079E68-F974-44A5-AB96-6720C475D165Q27860650-4BED17E4-56FC-4110-894B-06E518D9C907Q27860852-5D689FCF-3B9E-40D1-A708-AC583010E5F0Q27860857-85766878-B0C4-4527-B398-06A5ABF8A64AQ28066199-F26DC42D-85B0-479F-BB2A-55C294561CCEQ28082259-6885D5BE-129B-4FBD-8536-B6C2C2C23B3AQ28304161-5599A713-0738-4104-A833-37A32463088DQ29619686-799DF431-6276-42B9-85B3-E17EB96CC180Q30275174-6DE9DED5-E45C-4119-A22F-08D9A14A2B46Q30417431-67109766-9B41-4FD5-8F58-DA31FCDE1D80Q30422001-DBE7CA12-FA55-4953-A354-1DB9955F5486Q30434304-34751C38-2FFF-4662-B8D1-3366B3B60708Q30488777-3597BDC2-960E-4F39-80AD-485F7D99A534Q33406287-67C5434D-4C6E-4768-92E0-93BFB71D2E78Q33528964-558249CA-4753-4321-8CEF-23F5B21E42CEQ33569771-15E4608D-9B41-4F32-82F3-5F3D83A92A18Q33591683-CFAB15AD-0275-4773-A342-943CD9194B5FQ33606111-B66B4D57-D8AC-4E3D-A602-A8B49358A863Q33645224-07D120A5-5494-40FF-A8A2-19D8625A4BB5Q33648411-7461523C-448E-4107-9C99-BC62AEDC4218Q33651093-F947BEEB-B9DC-40F4-80C3-EADEB812F688
P2860
PD-1 and PD-1 ligands: from discovery to clinical application.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
PD-1 and PD-1 ligands: from discovery to clinical application.
@en
type
label
PD-1 and PD-1 ligands: from discovery to clinical application.
@en
prefLabel
PD-1 and PD-1 ligands: from discovery to clinical application.
@en
P356
P1476
PD-1 and PD-1 ligands: from discovery to clinical application.
@en
P2093
Taku Okazaki
P304
P356
10.1093/INTIMM/DXM057
P50
P577
2007-07-02T00:00:00Z